Lv11
8 积分 2023-12-13 加入
A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC)
1小时前
求助中
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
1小时前
已完结
Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
1小时前
已完结
Quantitative ultrasound measurement of uterine contractility in adenomyotic vs. normal uteri: a multicenter prospective study
4个月前
已完结
Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis
6个月前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
7个月前
已完结
Comparing the clinical efficacy and safety of second-line targeted therapy and immunotherapy in patients with mid- to advanced stages of hepatocellular carcinoma - A systematic review and meta-analysis of randomized clinical trials
8个月前
已关闭
Drug Information Services Today: Current Role and Future Perspectives in Rational Drug Therapy
9个月前
已关闭
Does pharmaceutical information systems data inform decision-making in public healthcare? Utility of a national system in a limited resource setting
9个月前
已完结
Drug information services: initial experiences in Dresden
9个月前
已完结
皖公网安备34019202002308
